β¨ Medicine Approvals
3302
NEW ZEALAND GAZETTE, No. 112
28 SEPTEMBER 2006
Product: Logem
Active Ingredient: Lamotrigine 100mg
Dosage Form: Chewable/dispersible tablet
New Zealand Sponsor: Pacific Pharmaceuticals Limited
Manufacturer: Genpharm Inc., Etobicoke, Ontario, Canada
Product: Logem
Active Ingredient: Lamotrigine 200mg
Dosage Form: Chewable/dispersible tablet
New Zealand Sponsor: Pacific Pharmaceuticals Limited
Manufacturer: Genpharm Inc., Etobicoke, Ontario, Canada
Product: Logem
Active Ingredient: Lamotrigine 25mg
Dosage Form: Chewable/dispersible tablet
New Zealand Sponsor: Pacific Pharmaceuticals Limited
Manufacturer: Genpharm Inc., Etobicoke, Ontario, Canada
Product: Logem
Active Ingredient: Lamotrigine 50mg
Dosage Form: Chewable/dispersible tablet
New Zealand Sponsor: Pacific Pharmaceuticals Limited
Manufacturer: Genpharm Inc., Etobicoke, Ontario, Canada
Product: Sodium Cromoglycate Eye Drops
Active Ingredient: Sodium cromoglicate 2%w/v
Dosage Form: Eye drops, solution
New Zealand Sponsor: REX Medical Limited
Manufacturer: Cipla Limited, Salcette, Goa, India
Product: Vivotif Oral
Active Ingredient: Salmonella typhi strain TY21A Berna 2,000 million organisms
Dosage Form: Modified release capsule
New Zealand Sponsor: CSL New Zealand Limited
Manufacturer: Berna Biotech AG, Berne, Switzerland
Dated this 22nd day of September 2006.
GRAEME GILLESPIE, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go6740
Consent to the Distribution of a New Related Product
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new related product set out in the Schedule hereto:
Schedule
Product: Aveeno Soothing Bath Treatment
Active Ingredient: Oatmeal colloidal 100%w/w
Dosage Form: Powder
New Zealand Sponsor: Johnson & Johnson (New Zealand) Limited
Manufacturer: Patheon Inc. Burlington, Ontario, Canada
Dated this 22nd day of September 2006.
GRAEME GILLESPIE, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go6741
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Xigris
Active Ingredient: Drotrecogin alfa (activated) 20mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: DSM Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Note: This consent is valid for two years from 19 September 2006.
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2006, No 112
Gazette.govt.nz —
NZ Gazette 2006, No 112
β¨ LLM interpretation of page content
π₯ Approval of Logem Products
π₯ Health & Social Welfare22 September 2006
Medicine, Lamotrigine, Chewable/dispersible tablet, Pacific Pharmaceuticals
- GRAEME GILLESPIE, Acting Deputy Director-General, Public Health
π₯ Approval of Sodium Cromoglycate Eye Drops
π₯ Health & Social Welfare22 September 2006
Medicine, Sodium cromoglicate, Eye drops, REX Medical
- GRAEME GILLESPIE, Acting Deputy Director-General, Public Health
π₯ Approval of Vivotif Oral
π₯ Health & Social Welfare22 September 2006
Medicine, Salmonella typhi, Modified release capsule, CSL New Zealand
- GRAEME GILLESPIE, Acting Deputy Director-General, Public Health
π₯ Consent to Distribution of Aveeno Soothing Bath Treatment
π₯ Health & Social Welfare22 September 2006
Medicine, Oatmeal colloidal, Powder, Johnson & Johnson
- GRAEME GILLESPIE, Acting Deputy Director-General, Public Health
π₯ Renewal of Provisional Consent for Xigris
π₯ Health & Social Welfare22 September 2006
Medicine, Drotrecogin alfa, Powder for infusion, Eli Lilly
- GRAEME GILLESPIE, Acting Deputy Director-General, Public Health